Creso Pharma Past Earnings Performance
Past criteria checks 0/6
Creso Pharma's earnings have been declining at an average annual rate of -17.5%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 52.3% per year.
Key information
-17.5%
Earnings growth rate
35.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 52.3% |
| Return on equity | -65.8% |
| Net Margin | -241.1% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Creso Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 8 | -18 | 18 | 0 |
| 31 Mar 22 | 7 | -24 | 23 | 0 |
| 31 Dec 21 | 6 | -30 | 27 | 0 |
| 30 Sep 21 | 5 | -31 | 24 | 0 |
| 30 Jun 21 | 4 | -32 | 21 | 0 |
| 31 Mar 21 | 3 | -32 | 15 | 0 |
| 31 Dec 20 | 2 | -31 | 10 | 0 |
| 30 Sep 20 | 3 | -29 | 10 | 0 |
| 30 Jun 20 | 4 | -26 | 10 | 0 |
| 31 Mar 20 | 4 | -21 | 11 | 0 |
| 31 Dec 19 | 4 | -15 | 11 | 0 |
| 30 Sep 19 | 2 | -15 | 12 | 0 |
| 30 Jun 19 | 1 | -15 | 13 | 0 |
| 31 Mar 19 | 1 | -16 | 15 | 0 |
| 31 Dec 18 | 1 | -17 | 16 | 0 |
| 30 Sep 18 | 0 | -18 | 17 | 1 |
| 30 Jun 18 | 0 | -19 | 18 | 1 |
| 31 Mar 18 | 0 | -17 | 15 | 1 |
| 31 Dec 17 | 0 | -15 | 13 | 1 |
| 30 Sep 17 | 0 | -11 | 10 | 1 |
| 30 Jun 17 | 0 | -8 | 6 | 1 |
| 31 Mar 17 | 0 | -6 | 5 | 1 |
| 31 Dec 16 | 0 | -5 | 4 | 0 |
Quality Earnings: CPHOA is currently unprofitable.
Growing Profit Margin: CPHOA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPHOA is unprofitable, and losses have increased over the past 5 years at a rate of 17.5% per year.
Accelerating Growth: Unable to compare CPHOA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPHOA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Return on Equity
High ROE: CPHOA has a negative Return on Equity (-65.8%), as it is currently unprofitable.